 |
|
Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
Hiep Phan, Rick A. Weideman, Daisha J. Cipher, Linda A. Feagins
Intest Res. 2020;18(3):282-288. Published online 2020 Apr 7 DOI: https://doi.org/10.5217/ir.2019.09140
|
|
Citations to this article as recorded by
 Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis
Akshita Gupta, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Clinical Gastroenterology and Hepatology.2024; 22(3): 499. CrossRef Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model
Takeshi Takasago, Ryohei Hayashi, Yoshitaka Ueno, Misa Ariyoshi, Kana Onishi, Ken Yamashita, Yuichi Hiyama, Hidehiko Takigawa, Ryo Yuge, Yuji Urabe, Shiro Oka, Yasuhiko Kitadai, Shinji Tanaka, Kenji Fujiwara
PLOS ONE.2023; 18(3): e0283822. CrossRef Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
Ivo Klarin, Yoshihiro Moriwaki
Case Reports in Gastrointestinal Medicine.2023; 2023: 1. CrossRef Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
Young Bin Joo, Seung Min Jung, Yune-Jung Park, Ki-Jo Kim, Kyung-Su Park
Journal of Rheumatic Diseases.2022; 29(3): 162. CrossRef Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef Twenty Years of Targeted and Biologic Immunomodulatory Drugs
Julia Berman, Yarden Yavne, Yonatan Edel, Ori Elkayam, Victoria Furer, Daniel Shepshelovich
Mayo Clinic Proceedings.2022; 97(8): 1512. CrossRef Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
Namrata Singh, Christopher I. Li
Current Opinion in Rheumatology.2021; 33(3): 292. CrossRef Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Jihye Park, Jae Hee Cheon
Gut and Liver.2021; 15(5): 641. CrossRef
|